sodium iodide i-131 37 - 7400 mbq kapseli terapiaan
curium netherlands b.v. - 131i-sodiumiodide - kapseli terapiaan - 37 - 7400 mbq - natriumjodidi(131i)
thallous ti-201 chloride 37 mbq/ml injektioneste
curium netherlands b.v. - 201tl-thallium-chloride - injektioneste - 37 mbq/ml - tallium(201tl)kloridi
resonium jauhe oraalisuspensiota/peräruiskesuspensiota varten
sanofi oy - sodium polystyrene sulfonate - jauhe oraalisuspensiota/peräruiskesuspensiota varten - polystyreenisulfonaatti
sodium iodide i-123 37 mbq/ml injektioneste
curium netherlands b.v. - 123i-sodiumiodide - injektioneste - 37 mbq/ml - natriumjodidi(123i)
galieve 500 mg / 213 mg / 325 mg oraalisuspensio, annospussi
reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium bicarbonate - oraalisuspensio, annospussi - 500 mg / 213 mg / 325 mg - algiinihappo
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
gaviscon oraalisuspensio
nordic drugs ab - aluminium hydroxide gel, calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo
galieve mint oraalisuspensio, annospussi
reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio, annospussi - algiinihappo
galieve mint oraalisuspensio
reckitt benckiser healthcare (scandinavia) a/s - calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.